LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

PBI-4050, A NOVEL FIRST-IN-CLASS AGENT, REDUCES PULMONARY HYPERTENSION, LUNG REMODELING AND RIGHT VENTRICULAR DYSFUNCTION IN HEART FAILURE

Photo by freestocks from unsplash

Heart failure with reduced ejection fraction (HFrEF) causes lung remodeling characterized by myofibroblasts proliferation and fibrosis leading to a restrictive lung syndrome with pulmonary hypertension (PH) and right ventricular (RV)… Click to show full abstract

Heart failure with reduced ejection fraction (HFrEF) causes lung remodeling characterized by myofibroblasts proliferation and fibrosis leading to a restrictive lung syndrome with pulmonary hypertension (PH) and right ventricular (RV) dysfunction. PBI-4050 is a first-in-class synthetic analog with

Keywords: pulmonary hypertension; right ventricular; heart failure; lung remodeling; pbi 4050; ventricular dysfunction

Journal Title: Journal of the American College of Cardiology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.